

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Marion General Hospital 2. 441 North Wabash Ave. Marion, IN 46952-2690		In accordance with letter dated May 26, 2022, 3. License No.: 13-17956-01 is amended in its entirety to read as follows:	4. Expiration Date: June 30, 2024 5. Docket No.: 030-13726 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Fluorine-18	7. Chemical and/or physical form A. Any B. Any C. Any D. Liquid	8. Maximum amount that licensee may possess at any one time under this license A. As needed B. As needed C. 2 curies total D. 125 millicuries	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For use in medical instrument calibration, reference and transmission.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-17956-01

Amendment No. 64

Docket or Reference No.:
030-13726**CONDITIONS**

10. A. Licensed material listed in Item Nos. 6.A. through 6.C. may be used at the licensee's facilities located at 441 North Wabash Avenue, Marion, Indiana.
- B. Licensed material listed in Item Nos. 6.A., 6.B., 6.C. (outpatient procedures only and released in accordance with 10 CFR 35.75), and 6.D. may be used at 1410 West Bella Drive, Marion, Indiana.
11. The Radiation Safety Officer (RSO) for this license is Dakshesh S. Patel, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User

James A. Arata, M.D.

Andrew V. Barger, M.D.

Jonathon Berger, M.D.

John L. Bormann, M.D.

Daniel Branam, M.D.

Christian M. Fisher, M.D.

Jeremy D. Gilliam, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-17956-01

Docket or Reference No.:
030-13726

Amendment No. 64

Authorized User

Brett A. Hagedorn, M.D.

Eric V. Heatwole, M.D.

David B. Janizek, M.D.

Christopher M. Kowalski, M.D.

Jonathan Lee, M.D.

Michael E. Parker, M.D.

John Pasalich, M.D.

Dakshesh S. Patel, M.D.

Randall J. Phillips, M.D.

John Rock, M.D.

Richard W. Sibley, M.D.

Rik Stephens, M.D.

Andre B. Stovall, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

C. The following individuals are authorized users for nonmedical uses as indicated:

Non-Medical Use

Rachel L. Delaney Culp, CNMT

Keith A. Vice, CNMT, NMTCB(PET)

Material and Use

Fluorine-18 in medical instrument calibration, reference, and transmission

Fluorine-18 in medical instrument calibration, reference, and transmission

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 13-17956-01

Amendment No. 64

Docket or Reference No.:
030-13726

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated January 2, 2014 (ML14015A385)
- B. Letter dated May 9, 2014 (ML14135A271)
- C. Letter dated April 4, 2017 (ML17163A403)
- D. Letter dated July 27, 2017 (ML17215B010)
- E. Letter dated March 1, 2019 (ML19071A313)
- F. Letter dated March 5, 2020 (ML20069J094)
- G. Letter dated April 3, 2020 (ML20128J622)



FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date: August 12, 2022By: _____
Bryan A. Parker
Region III